Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

This $674 Million Deal Aims To Turn Your Body's Garbage Disposal Into A Disease Fighter

Feb 13, 2024 - forbes.com
VantAI, a pharmaceutical company, is using generative AI to design "molecular glues" that can activate protein degraders in the body, tricking it into eliminating disease-causing agents. The company recently announced a partnership with Bristol Myers Squibb to develop these molecular glues as potential drugs, with VantAI eligible to receive up to $674 million in research milestone payments and royalties for any approved drugs resulting from the collaboration.

Founded in 2019 by Zachary Carpenter and Luca Naef, VantAI is part of the Roivant umbrella of pharmaceutical companies. The company's technology is built on generative AI models and graph theory, and it also has multi-year collaborations with Janssen Pharmaceutica NV, Boehringer Ingelheim, and Blueprint Medicines, potentially worth up to $3 billion in research milestone payments.

Key takeaways:

  • VantAI, a company that uses generative AI to design 'molecular glues' that can be used as drugs, has partnered with pharmaceutical giant Bristol Myers Squibb to develop new molecular glues.
  • The company will receive an undisclosed upfront payment and could receive up to $674 million in research milestone payments, as well as royalties for sales of any drug approved as a result of the collaboration.
  • VantAI was founded in 2019 by Zachary Carpenter and Luca Naef and is part of the Roivant umbrella of pharmaceutical companies established by billionaire Vivek Ramaswamy.
  • VantAI also has multi-year collaborations with Janssen Pharmaceutica NV, Boehringer Ingelheim, and Blueprint Medicines, potentially worth up to $3 billion in research milestone payments.
View Full Article

Comments (0)

Be the first to comment!